Fresenius Group Overview

  • H1 & Q2 2018 Results

    Fresenius posts strong second quarter and confirms Group guidance – Continued net income growth – EBIT outlook raised for Fresenius Kabi

New Developments

Financial Highlights


€ 8382 m

+5%1, 2

Q2/2017: €8,401 m2


€ 1509 m


Q2/2017: €1,538 m


€ 1145 m


Q2/2017: €1,177 m



Dec. 31, 2017: 273,249

Net Income3

€ 472 m


Q2/2017: €459 m

Earnings per Share3

€ 0.85


Q2/2017: €0.82


1 In constant currency, before special items

2 Adjusted for IFRS 15 adoption

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

CEO message

“The first half of 2018 was a very good one for Fresenius. After our successful start, we have delivered a strong second quarter with continued healthy growth in sales and earnings. All four business segments contributed to this, and all four business segments display outstanding prospects for the future. For Fresenius Kabi, we are even a bit more optimistic than before. We are therefore fully on track to achieve our ambitious growth targets as we steer toward another excellent year for Fresenius.”

Stephan Sturm, Chairman of the Management Board 

  • Business Segments

    • Q2/2018 reported results significantly positively influenced by divestitures of Care Coordination activities
    • 5% adjusted sales growth in constant currency
    • 6% adjusted net income growth in constant currency
    • 22% net income growth in constant currency on a comparable basis

  • Business Segments

    • 6% organic sales growth and 11% EBIT growth in constant currency (excluding biosimilars business)
    • European Commission confirms marketing authorizations of HES subject to the implementation of risk minimization measures
    • Sales outlook confirmed
    • EBIT outlook raised

  • Business Segments

    • 4% organic sales growth
    • DRG catalogue effects and preparatory structural activities for anticipated regulatory measures weigh on financial performance of Helios Germany
    • Helios Spain with accelerated growth: 8% organic sales growth and 19% EBIT growth
    • 2018 outlook confirmed

  • Business Segments

    • Service business with continued good momentum: 11% sales growth
    • Project business with good order intake of €195 million
    • Transfer of inpatient post-acute care business from Helios Germany to Vamed as of July 1, 2018
    • 2018 outlook confirmed

Fresenius Helios Capital Markets Day

The management teams of Fresenius and Fresenius Helios presented and discussed in detail Fresenius Helios’ business, strategy and growth prospects.

A detailed agenda and the presentation slides are available on our website. We will soon host a replay of the webcast and Q&A sessions from the Fresenius Helios Capital Markets Day.


All Financial Reports